Arca
Skip to content
Tools
Tools

Interleukin-15 receptor

Complex in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on IL15RA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1
  • Other 1

Approved1

Phase 30

    Phase 21

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      Nogapendekin alfa inbakiceptApprovedAltor BioScienceProtein or peptideAgonistInterleukin-15 receptor agonist10
      Recombinant human interleukin-15Phase 2ImmunityBioOtherAgonistInterleukin-15 receptor agonist3

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
      NAI Plus Standard of Care Compared To SOC Alone Plus Standard of Care in Critically Ill Adults With SepsisNogapendekin alfa inbakiceptPhase 2Not yet recruitingImmunityBio, Inc.Aug 25, 2026
      Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNogapendekin alfa inbakiceptPhase 2Not yet recruitingImmunityBio, Inc.Jun 4, 2026
      First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerNogapendekin alfa inbakiceptPhase 1 / Phase 2RecruitingWashington University School of MedicineJan 21, 2026
      N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular TherapyNogapendekin alfa inbakiceptEarly phase 1RecruitingSeth PollackDec 3, 2025
      N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNogapendekin alfa inbakiceptPhase 1Not yet recruitingImmunityBio, Inc.Oct 16, 2025
      A Study to Examine Anktiva for the Treatment of COVID-19.Nogapendekin alfa inbakiceptPhase 2RecruitingImmunityBio, Inc.Aug 14, 2025
      A Study to Assess Anktiva in Patients With Long Covid-19.Nogapendekin alfa inbakiceptPhase 2RecruitingImmunityBio, Inc.Aug 6, 2025
      PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCRecombinant human interleukin-15Phase 2RecruitingDana-Farber Cancer InstituteFeb 2, 2024
      N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNogapendekin alfa inbakiceptPhase 2Active, not recruitingImmunityBio, Inc.Sep 29, 2023
      Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaRecombinant human interleukin-15Phase 1RecruitingImmunityBio, Inc.Nov 16, 2022
      Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerRecombinant human interleukin-15Phase 2Active, not recruitingImmunityBio, Inc.May 15, 2020

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4665592, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.